View All Documents & Correspondence
Monovalent And Polyvalent Synthetic Polysaccharide Antigens For Immunological Intervention In Disease
Abstract: The present invention provides a pro-inflammatory synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2 -targeting synthetic peptidoglycan (PGN) moiety onto which a first epitope and a second epitope are each covalently attached. The first epitope comprises one or more than one generic T helper peptide sequence, and the second epitope comprises one or more than one target epitope. The first and second epitopes are present in one or more copies each within the SPA. Each target epitope is a peptide sequence or a carbohydrate moiety, and is an immunogen to CD8+ T cells or B cells. The present invention also provides a suppressive synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which one or more than one target epitope is covalently attached. Each target epitope is a peptide sequence or carbohydrate moiety and is present in one or more copies within the SPA.
Notices, Deadlines & Correspondence
Patent Information
Applicants
ELI LILLY AND COMPANY
Inventors
1. BLASZCZAK, LARRY, CHRIS
Specification
The present invention provides a pro-inflammatory synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2 -targeting synthetic
peptidoglycan (PGN) moiety onto which a first epitope and a second epitope are each
covalently attached. The first epitope comprises one or more than one generic T helper
peptide sequence, and the second epitope comprises one or more than one target epitope. The first and second epitopes are present in one or more copies each within the SPA. Each target
epitope is a peptide sequence or a carbohydrate moiety, and is an immunogen to CD8+ T
cells or B cells. The present invention also provides a suppressive synthetic polysaccharide
antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting
synthetic peptidoglycan (PGN) moiety onto which one or more than one target epitope is
covalently attached. Each target epitope is a peptide sequence or carbohydrate moiety and is
present in one or more copies within the SPA.
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 4233-KOLNP-2007-FORM 3.1.2.pdf | 2011-10-08 |
| 2 | 4233-KOLNP-2007-FORM 3-1.1.pdf | 2011-10-08 |
| 3 | 4233-kolnp-2007-form 18.pdf | 2011-10-08 |
| 4 | 4233-KOLNP-2007-FORM 13.pdf | 2011-10-08 |
| 5 | 4233-KOLNP-2007-FORM 1-1.1.pdf | 2011-10-08 |
| 6 | 4233-KOLNP-2007-CORRESPONDENCE-1.2.pdf | 2011-10-08 |
| 7 | 4233-KOLNP-2007-CORRESPONDENCE OTHERS 1.1.pdf | 2011-10-08 |
| 8 | 4233-KOLNP-2007-CORRESPONDENCE 1.1.pdf | 2011-10-08 |
| 9 | 04233-kolnp-2007-pct priority document notification.pdf | 2011-10-08 |
| 10 | 04233-kolnp-2007-international publication.pdf | 2011-10-08 |
| 11 | 04233-kolnp-2007-gpa.pdf | 2011-10-08 |
| 12 | 04233-kolnp-2007-form 5.pdf | 2011-10-08 |
| 13 | 04233-kolnp-2007-form 3.pdf | 2011-10-08 |
| 14 | 04233-kolnp-2007-form 2.pdf | 2011-10-08 |
| 15 | 04233-kolnp-2007-form 1.pdf | 2011-10-08 |
| 16 | 04233-kolnp-2007-drawings.pdf | 2011-10-08 |
| 17 | 04233-kolnp-2007-correspondence others.pdf | 2011-10-08 |
| 18 | 04233-kolnp-2007-claims.pdf | 2011-10-08 |
| 19 | 04233-kolnp-2007-abstract.pdf | 2011-10-08 |
| 20 | 4233-KOLNP-2007-(03-11-2011)-FORM 3.pdf | 2011-11-03 |
| 21 | 4233-KOLNP-2007-(03-11-2011)-CORRESPONDENCE.pdf | 2011-11-03 |
| 22 | 4233-KOLNP-2007-(28-10-2013)-ABANDONED LETTER.pdf | 2013-10-28 |
| 23 | 4233-KOLNP-2007_EXAMREPORT.pdf | 2016-06-30 |
| 24 | 4233-KOLNP-2007-ABANDONED LETTER.pdf | 2016-10-07 |
| 25 | 4233-KOLNP-2007-INTERNATIONAL PUBLICATION.pdf | 2017-01-13 |
| 26 | 4233-KOLNP-2007-FIRST EXAMINATION REPORT.pdf | 2017-01-13 |
| 27 | 4233-KOLNP-2007-INTERNATIONAL SEARCH REPORT & OTHERS.pdf | 2018-09-24 |
| 28 | 4233-KOLNP-2007-CORRESPONDENCE.pdf | 2018-09-24 |
| 29 | 4233-KOLNP-2007-PCT SEARCH REPORT.pdf | 2018-09-26 |
| 30 | 4233-KOLNP-2007-CORRESPONDENCE-1-1.pdf | 2018-09-26 |